Harold Eugene Brakewood - Net Worth and Insider Trading

Harold Eugene Brakewood Net Worth

The estimated net worth of Harold Eugene Brakewood is at least $9,087 dollars as of 2024-12-28. Harold Eugene Brakewood is the Chief Business Officer of Immuneering Corp and owns about 3,900 shares of Immuneering Corp (IMRX) stock worth over $9,087. Details can be seen in Harold Eugene Brakewood's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Harold Eugene Brakewood has not made any transactions after 2024-03-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Harold Eugene Brakewood

To

Harold Eugene Brakewood Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Harold Eugene Brakewood owns 1 companies in total, including Immuneering Corp (IMRX) .

Click here to see the complete history of Harold Eugene Brakewood’s form 4 insider trades.

Insider Ownership Summary of Harold Eugene Brakewood

Ticker Comapny Transaction Date Type of Owner
IMRX Immuneering Corp 2024-03-22 Chief Business Officer

Harold Eugene Brakewood Latest Holdings Summary

Harold Eugene Brakewood currently owns a total of 1 stock. Harold Eugene Brakewood owns 3,900 shares of Immuneering Corp (IMRX) as of March 22, 2024, with a value of $9,087.

Latest Holdings of Harold Eugene Brakewood

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
IMRX Immuneering Corp 2024-03-22 3,900 2.33 9,087

Holding Weightings of Harold Eugene Brakewood


Harold Eugene Brakewood Form 4 Trading Tracker

According to the SEC Form 4 filings, Harold Eugene Brakewood has made a total of 1 transactions in Immuneering Corp (IMRX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Immuneering Corp is the acquisition of 3,900 shares on March 22, 2024, which cost Harold Eugene Brakewood around $10,023.

Insider Trading History of Harold Eugene Brakewood

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Harold Eugene Brakewood Trading Performance

GuruFocus tracks the stock performance after each of Harold Eugene Brakewood's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Harold Eugene Brakewood is -43.92%. GuruFocus also compares Harold Eugene Brakewood's trading performance to market benchmark return within the same time period. The performance of stocks bought by Harold Eugene Brakewood within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Harold Eugene Brakewood's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Harold Eugene Brakewood

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -32.55 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -28.28 LIMIT LIMIT LIMIT LIMIT LIMIT

Harold Eugene Brakewood Ownership Network

Ownership Network List of Harold Eugene Brakewood

No Data

Ownership Network Relation of Harold Eugene Brakewood

Insider Network Chart

Harold Eugene Brakewood Owned Company Details

What does Immuneering Corp do?

Who are the key executives at Immuneering Corp?

Harold Eugene Brakewood is the Chief Business Officer of Immuneering Corp. Other key executives at Immuneering Corp include 10 percent owner Cormorant Asset Management, Lp , Vice President & Finance Mallory Morales , and Chief Scientific Officer Brett Matthew Hall .

Immuneering Corp (IMRX) Insider Trades Summary

Over the past 18 months, Harold Eugene Brakewood made 1 insider transaction in Immuneering Corp (IMRX) with a net purchase of 3,900. Other recent insider transactions involving Immuneering Corp (IMRX) include a net sale of 1,309,091 shares made by Cormorant Asset Management, Lp , a net purchase of 100,000 shares made by Peter Feinberg , and a net purchase of 57,965 shares made by Ann E Berman .

In summary, during the past 3 months, insiders sold 0 shares of Immuneering Corp (IMRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,309,091 shares of Immuneering Corp (IMRX) were sold and 197,083 shares were bought by its insiders, resulting in a net sale of 1,112,008 shares.

Immuneering Corp (IMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Immuneering Corp Insider Transactions

No Available Data

Harold Eugene Brakewood Mailing Address

Above is the net worth, insider trading, and ownership report for Harold Eugene Brakewood. You might contact Harold Eugene Brakewood via mailing address: C/o Immuneering Corporation, 245 Main Street, Second Floor, Cambridge Ma 02142.

Discussions on Harold Eugene Brakewood

No discussions yet.